Strong population-level hybrid immunity from prior infections and repeated vaccinations continues to limit SARS-CoV-2 transmission and severe outcomes, keeping global test positivity rates below 5% and reported cases far below pandemic thresholds through mid-2026. Official surveillance from WHO and CDC shows moderate overall risk, with circulating variants such as XFG and BA.2.86 lineages monitored for immune escape but not yet linked to exponential growth or elevated hospitalization rates. Low ICU occupancy and steadily declining weekly deaths further support trader consensus on the “No” outcome. A realistic challenge would require emergence of a novel, highly virulent strain capable of rapid immune evasion and widespread severe disease before updated monovalent vaccines can be deployed at scale.